Blood test catches cancer early; drug aims to stop return
NCT ID NCT07292207
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether monitoring tumor DNA in the blood (ctDNA) and treating with abemaciclib can prevent breast cancer from coming back. 30 people with HR+/HER2- breast cancer who have finished standard treatment will be followed. If ctDNA is detected, they will receive abemaciclib to try to clear it and stop recurrence.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Nagoya City University
Nagoya, Japan
Contact Phone: •••-•••-•••• Email: •••••@•••••